Burjeel Holdings has announced the launch of the Burjeel Cancer Institute (BCI) in Mohammed bin Zayed City, Abu Dhabi, UAE.
UAE Minister of Tolerance and Coexistence Sheikh Nahyan bin Mubarak Al Nahyan inaugurated the new cancer care facility.
The facility, which resides within Burjeel Medical City, is poised to provide advanced cancer treatments to patients within the UAE and internationally.
The network caters to more than 5,000 oncology patients, conducts upwards of 10,000 screenings, and administers over 10,000 radiotherapy sessions annually.
BCI’s team includes over 50 specialists who deliver comprehensive cancer care.
The institute’s dedicated tower spans four floors and houses private chemotherapy suites, speciality clinics, and a bespoke breast cancer unit.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBCI integrates a variety of treatments such as immunotherapy, chemotherapy and surgical oncology, along with advanced technologies like stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT).
It offers precision medicine, targeted therapy and advanced surgical and radiation therapies and also utilises AI for cancer diagnosis and management.
Burjeel Holdings founder and chairman Dr Shamsheer Vayalil said: “The launch of BCI marks a significant milestone in our journey to provide world-class cancer care within the UAE.
“We are committed to ensuring that patients receive the best possible care, supported by advanced technology and research. We believe that BCI will transform cancer treatment and significantly improve patient outcomes.”
Advanced diagnostic capabilities at BCI are bolstered by OncoHelix-CoLab, which enables specialised tests to be performed locally.
Technologies such as Droplet Digital PCR, next-generation sequencing (NGS) and multi-colour flow cytometry are employed to improve diagnostic accuracy and patient outcomes.
BCI also plans to set up educational programmes, support research, and develop residency and fellowship programmes in partnership with both local and global institutions. The institute will also engage in community outreach through awareness campaigns, educational seminars, and cancer screening initiatives.